| Biomarker | OPNb/OPNc | Full name | Osteopontin isoform b/isoform c | Molecular Type | Protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis (recurrent-related) | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow (real-time quantitative PCR) | ||
| Pathobiological Mechanisms | Persistent overexpression after chemotherapy, associated with the VEGFc/STAT3/CXCR4 pathway, promotes recurrence. | ||||
| Clinical Availability Status | Research validation: Overexpression was more pronounced in the M0, M1, and M2 subgroups. | ||||
| Notes and Dynamics | It can serve as a biomarker for the recurrence of AML, requiring further clinical validation. | ||||
| Biomarker | B type natriuretic peptide | Full name | Brain natriuretic peptide | Molecular Type | Protein |
| Molecular Formula | / | Molecular Weight | 4 kDa | Core Functional Dimensions | Prognosis, Monitoring |
| Disease(or Constitution) | Myocarditis | Disease Subtypes | / | ||
| Organ | Myocardium | Test Sample / Technology Platform | Serum/Plasma (ELISA) | ||
| Pathobiological Mechanisms | Myocardium is released during stretching or cardiac insufficiency, reflecting ventricular load | ||||
| Clinical Availability Status | Clinically available | ||||
| Notes and Dynamics | Assist in assessing cardiac function and predicting the risk of heart failure | ||||
| Biomarker | circZBTB46 | Full name | Circular Zinc Finger And BTB Domain Containing 46 | Molecular Type | Nucleic acid (circRNA) |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, prognosis, therapeutic targets | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow/AML cell lines (qRT-PCR, RNA sequencing) | ||
| Pathobiological Mechanisms | As a miRNA sponge, it upregulates SCD expression and protects AML cells from ferroptosis | ||||
| Clinical Availability Status | Cutting-edge Research: Demonstrates high sensitivity and specificity for AML diagnosis. | ||||
| Notes and Dynamics | Associated with ferroptosis, combination with ferroptosis inducers may enhance therapeutic efficacy. | ||||
| Biomarker | TROAP | Full name | Trophinin Associated Protein | Molecular Type | Protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis (cytogenetically normal AML) | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow (RNA sequencing, qRT-PCR) | ||
| Pathobiological Mechanisms | High expression is associated with chemosensitivity, while low expression is observed in leukemia stem cells. | ||||
| Clinical Availability Status | Research validation: Can serve as an independent prognostic predictor for CN-AML. | ||||
| Notes and Dynamics | The expression level is associated with drug susceptibility to multiple agents, guiding the selection of chemotherapy regimens. | ||||
| Biomarker | FIBP | Full name | Fibroblast Growth Factor Binding Protein 1 | Molecular Type | Protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis, immune infiltration-related | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow (RNA sequencing, qRT-PCR) | ||
| Pathobiological Mechanisms | Participates in leukocyte migration, adhesion, and T-cell tolerance induction, and is associated with immune cell infiltration. | ||||
| Clinical Availability Status | Study validation: Significantly shortened overall survival in the high-expression group. | ||||
| Notes and Dynamics | Positively correlated with CD4, IL-10, and IL-2, providing a basis for combined immunotherapy. | ||||
| Biomarker | cTnI / cTnT | Full name | Cardiac troponin I / Cardiac troponin T | Molecular Type | Protein |
| Molecular Formula | / | Molecular Weight | cTnI: 24 kDa; cTnT: 37 kDa | Core Functional Dimensions | Diagnosis, Prognosis |
| Disease(or Constitution) | Myocarditis | Disease Subtypes | / | ||
| Organ | Myocardium | Test Sample / Technology Platform | Serum/plasma (ELISA, SIMOA) | ||
| Pathobiological Mechanisms | Myocardial cell damage after release, reflecting the degree of myocardial necrosis | ||||
| Clinical Availability Status | Clinically available (recommended by guidelines) | ||||
| Notes and Dynamics | Core myocarditis diagnostic markers, high specificity and sensitivity, is one of the gold standard | ||||
| Biomarker | STMN1 | Full name | Stathmin 1 | Molecular Type | Protein |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognosis, therapeutic targets | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Peripheral blood mononuclear cells/bone marrow (RT-PCR, Western blot, flow cytometry) | ||
| Pathobiological Mechanisms | Activates the PI3K/Akt pathway, promotes cell proliferation, and inhibits apoptosis, resulting in G1 phase arrest | ||||
| Clinical Availability Status | Research verification: Expression levels correlate with FAB subtype, risk stratification, and survival duration. | ||||
| Notes and Dynamics | Inhibition of STMN1 upregulates caspase3 and Bax, providing a therapeutic target. | ||||
| Biomarker | miR-181d | Full name | MicroRNA-181d | Molecular Type | Nucleic acid (miRNA) |
| Molecular Formula | / | Molecular Weight | 6.6 kDa | Core Functional Dimensions | diagnosis |
| Disease(or Constitution) | Myocarditis | Disease Subtypes | / | ||
| Organ | Myocardium, immune cells | Test Sample / Technology Platform | Serum (qPCR) | ||
| Pathobiological Mechanisms | It cooperates with miR-30a to regulate inflammatory pathways | ||||
| Clinical Availability Status | Study validation | ||||
| Notes and Dynamics | The expression is up-regulated in the serum of VM patients, which can distinguish VM from healthy people | ||||
| Biomarker | CLEC10A | Full name | C-Type Lectin Domain Family 10 Member A | Molecular Type | Nucleic acid (RNA) |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis (related to thrombocytopenia) | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow (RNA sequencing, qRT-PCR) | ||
| Pathobiological Mechanisms | Participates in bone remodeling and immune-related pathways, associated with the interference of leukemia cells on platelet function | ||||
| Clinical Availability Status | Research verification: Incorporating low platelet count into AML prediction model. | ||||
| Notes and Dynamics | Provide a new perspective for understanding the pathophysiological mechanisms of low platelet AML. | ||||
| Biomarker | miR-30a | Full name | MicroRNA-30a | Molecular Type | Nucleic acid (miRNA) |
| Molecular Formula | / | Molecular Weight | 6.6 kDa | Core Functional Dimensions | diagnosis |
| Disease(or Constitution) | Myocarditis | Disease Subtypes | / | ||
| Organ | Myocardium, immune cells | Test Sample / Technology Platform | Serum (qPCR) | ||
| Pathobiological Mechanisms | Targeting SOCS3 gene to regulate myocardial inflammation | ||||
| Clinical Availability Status | Study validation | ||||
| Notes and Dynamics | CVB3-induced VM mice significantly increased | ||||
| Biomarker | TNFSF15 | Full name | Tumor Necrosis Factor Superfamily Member 15 | Molecular Type | Nucleic acid (RNA) |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis (related to thrombocytopenia) | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow (RNA sequencing, qRT-PCR) | ||
| Pathobiological Mechanisms | Participates in the regulation of inflammatory and cytokine pathways, influencing platelet activation mechanisms. | ||||
| Clinical Availability Status | Research verification: Collaborative prediction of low platelet AML with CSF1R. | ||||
| Notes and Dynamics | Study on the first biomarker related to thrombocytopenia in the data of basic RNA expression. | ||||
| Biomarker | CSF1R | Full name | Colony Stimulating Factor 1 Receptor | Molecular Type | Nucleic acid (RNA) |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis (related to thrombocytopenia) | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow (RNA sequencing, qRT-PCR) | ||
| Pathobiological Mechanisms | Participates in the G protein-coupled receptor pathway, cytokine pathway, and is associated with thrombocytopenia mechanisms. | ||||
| Clinical Availability Status | Research validation: The AUC value of the support vector machine model reached 0.847. | ||||
| Notes and Dynamics | Providing molecular basis for the diagnosis of thrombocytopenia in patients with normal karyotype AML. | ||||
| Biomarker | miR-155 | Full name | MicroRNA-155 | Molecular Type | Nucleic acid (miRNA) |
| Molecular Formula | / | Molecular Weight | 6.6 kDa | Core Functional Dimensions | Diagnosis and monitoring |
| Disease(or Constitution) | Myocarditis | Disease Subtypes | / | ||
| Organ | Immune cells, myocardium | Test Sample / Technology Platform | Serum/Plasma (qPCR) | ||
| Pathobiological Mechanisms | Regulation of macrophage polarization and the release of inflammatory factors | ||||
| Clinical Availability Status | Study validation | ||||
| Notes and Dynamics | It is highly expressed in VM and ICI myocarditis and positively correlated with the degree of inflammation | ||||
| Biomarker | CK-MB | Full name | Creatine kinase MB isoenzyme | Molecular Type | Proteins |
| Molecular Formula | / | Molecular Weight | 86 kDa | Core Functional Dimensions | diagnosis |
| Disease(or Constitution) | Myocarditis | Disease Subtypes | / | ||
| Organ | Myocardium | Test Sample / Technology Platform | Serum (ELISA and immunoblot) | ||
| Pathobiological Mechanisms | Myocardial specific isoenzymes that are preferentially released after myocardial injury | ||||
| Clinical Availability Status | Clinical available | ||||
| Notes and Dynamics | The specificity is higher than that of total CK, which is helpful in the diagnosis of myocardial injury | ||||
| Biomarker | t(8;21)/inv(16)/t(16;16) fusion transcript | Full name | t(8;21) (RUNX1-RUNX1T1)/inversion 16 (CBFβ-MYH11)/t(16;16) (CBFβ-MYH11) fusion transcript | Molecular Type | Nucleic acid (RNA) |
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, monitoring, prognosis | ||
| Disease(or Constitution) | Acute Myeloid Leukemia (AML) | Disease Subtypes | / | ||
| Organ | Blood, bone marrow | Test Sample / Technology Platform | Bone marrow (quantitative polymerase chain reaction, QPCR) | ||
| Pathobiological Mechanisms | Chromosomal translocation generates fusion proteins, driving leukemia development and sensitivity to chemotherapy | ||||
| Clinical Availability Status | Clinically available/guideline-recommended: Included in the CBF-AML diagnostic criteria for efficacy monitoring. | ||||
| Notes and Dynamics | The first-line treatment regimen combining rituximab and oxorubicin improves prognosis, and continuous monitoring of fusion transcripts guides treatment adjustments. | ||||
| Biomarker | CK | Full name | Creatine kinase | Molecular Type | Protein |
| Molecular Formula | / | Molecular Weight | 86 kDa | Core Functional Dimensions | Diagnosis, Monitoring |
| Disease(or Constitution) | Myocarditis | Disease Subtypes | / | ||
| Organ | Myocardium, skeletal muscle, brain | Test Sample / Technology Platform | Serum (colorimetric method, ELISA) | ||
| Pathobiological Mechanisms | Myocardial or skeletal muscle is released after injury, suggesting myocyte damage | ||||
| Clinical Availability Status | Clinically available | ||||
| Notes and Dynamics | Non-specific, contract enzyme detection is required | ||||